Find Clinical Trial

A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

IndicationBlood cancer
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

UCART19,
S068587

Active Substance CodeS068587
Protocol CodeCL1-68587-003
EudraCT Code2016-000297-38
NCT CodeNCT02735083


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



More information

UCART-19  is anti-CD-19 allogenic CAR-T product developed based on exclusive license granted by Cellectis to Servier. UCART-19 uses Cellectis’ technologies, including TALEN® gene-editing technologies

© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility